Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

BACKGROUND: Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients with HF an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Eiichiro, Rastogi, Anjay, Murohara, Toyoaki, Lesén, Eva, Agiro, Abiy, Arnold, Matthew, Chen, Gengshi, Yajima, Toshitaka, Järbrink, Krister, Pollack, Charles V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854063/
https://www.ncbi.nlm.nih.gov/pubmed/36658531
http://dx.doi.org/10.1186/s12882-022-03054-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854063/
https://www.ncbi.nlm.nih.gov/pubmed/36658531
http://dx.doi.org/10.1186/s12882-022-03054-5

Ejemplares similares